Clomethiazole

Summary

Clomethiazole (CHEMBL315795) is an approved small molecule (ATC N05CM02); indicated across 4 conditions including anxiety and dementia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM02 (+1 more)
• Indications: 4 conditions
• Clinical trials: 1
• Chemistry: 161.65 Da · C6H8ClNS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL315795
Name	Clomethiazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10783
ATC	N05CM02, N05CX04
Molecular formula	C6H8ClNS
Molecular weight	161.65
InChIKey	PCLITLDOTJTVDJ-UHFFFAOYSA-N

SMILES: CC1=C(SC=N1)CCCl

IUPAC name: 5-(2-chloroethyl)-4-methyl-1,3-thiazole

Also known as: Chlormethiazole, Clomethiazole, Clometiazol, Distraneurine, Heminevrin, SID11113756, SID26751938, SID90341262, clomethiazole, CHLORMETHIAZOLE, SID144204482, SID170466516

Patent coverage: 1,171 distinct patent families (4,740 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 14 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.65	Potency	22.4	nM	CHEMBL_ACT_3653675
CYP2C9	5.6	Potency	2512	nM	CHEMBL_ACT_5029527
CYP2C9	5.6	AC50	2512	nM	CHEMBL_ACT_5993391
CYP2C19	5.1	Potency	7943	nM	CHEMBL_ACT_4021501
CYP2C19	5.1	AC50	7943	nM	CHEMBL_ACT_6061061

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).